Ysios Capital participates in its portfolio company Galecto $64 Million financing to accelerate development of clinical pipeline

28/09/2020 Press release GALECTO RAISES $64 MILLION TO ACCELERATE DEVELOPMENT OF CLINICAL PIPELINE.   Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful…